Osteosarcoma profiling reveals why immunotherapy remains ineffective
(University of Texas M. D. Anderson Cancer Center) Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally poor responses observed from treatment with immune checkpoint inhibitors, according to new research from The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2020 Category: Cancer & Oncology Source Type: news

Gilberto Lopes, MD, MBA, FAMS, on Stopping Immunotherapy in Patients With Lung Cancer
Gilberto Lopes, MD, MBA, FAMS, discussed his presentation about when to stop immunotherapy treatments for patients with lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 21, 2020 Category: Cancer & Oncology Authors: Gilberto Lopes, MD, MBA, FAMS Source Type: news

Germany's Immatics ties up with GSK to develop immunotherapies
German biopharmaceutical firm Immatics said on Thursday it plans to collaborate with British drugmaker GlaxoSmithKline (GSK) to develop immunotherapies targeting multiple cancer indications, with a focus on solid tumours. (Source: Reuters: Health)
Source: Reuters: Health - February 20, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Rogerio Lilenbaum, MD, Discusses Immunotherapy and Targeted Therapy for Lung Cancer
Rogerio Lilenbaum, MD, talked about the state of lung cancer in regards to immunotherapy and targeted therapy at the 17th Annual Winter Lung Conference in Miami Beach, Florida. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2020 Category: Cancer & Oncology Authors: Rogerio Lilenbaum, MD Source Type: news

Newly discovered immune cell type may be key to improving pancreatic cancer immunotherapy
(Memorial Sloan Kettering Cancer Center) Current immunotherapies don't work for most people with cancer. Researchers have identified an overlooked immune cell type that may react to targeted therapies to rally a more powerful immune response in more cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2020 Category: Cancer & Oncology Source Type: news

New mechanism involved in senescence modulates inflammation, response to immunotherapy
(The Wistar Institute) Wistar scientists discovered a novel pathway that enables detection of DNA in the cytoplasm and triggers inflammation and cellular senescence. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 19, 2020 Category: Biology Source Type: news

New study finds cellular immunotherapy treatment associated with improved quality of life
(American Society of Hematology) Adult lymphoma patients whose disease was effectively treated with chimeric antigen receptor T-cell (CAR-T) therapy showed marked improvement on a variety of self-reported quality of life measures, according to a study published today in Blood Advances. The study offers evidence that CAR-T may not only extend cancer patients' survival, but also improve their quality of life after treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2020 Category: Cancer & Oncology Source Type: news

Mesothelioma Detection May Come Earlier with Liquid Biopsy
Cellular Analytics, a biotechnology company in Ontario, Canada, has unveiled a novel liquid biopsy test for mesothelioma that could lead to more effective management of this rare cancer. The test has the potential to produce a much-earlier diagnosis of disease and the ability to personalize treatment and better predict a patient’s response to specific therapies. “We could change completely how this disease is viewed,” Dr. Brent Zanke, a specialist in diagnostic oncology and chief executive officer of Cellular Analytics, told The Mesothelioma Center at Asbestos.com. “It’s a proactive way to get...
Source: Asbestos and Mesothelioma News - February 18, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Predicting immunotherapy success
One of the frustrations with anti-cancer therapy is that no one drug fits all: Most work well in some people but have little effect in other patients with the same type of cancer. This is as true of the newer immunotherapy treatments as it is of older types of chemotherapy. Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments. (Source: World Pharma News)
Source: World Pharma News - February 18, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Predicting immunotherapy success
(Weizmann Institute of Science) Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 18, 2020 Category: International Medicine & Public Health Source Type: news

Navidea raises $7.6M, regains listing compliance
Radiopharmaceutical developer Navidea Biopharmaceuticals announced that it...Read more on AuntMinnie.comRelated Reading: Navidea claims victories in legal case with former CEO Navidea signs immunotherapy deal with IMV Navidea highlights rheumatoid arthritis results Navidea teams up with UAB to win NIH grant Navidea posts Q2 revenue decreases (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 17, 2020 Category: Radiology Source Type: news

Cancer immunotherapy target helps fight solid tumors
(Biophysical Society) Yvonne Chen engineers immune cells to target their most evasive enemy: cancer. New cancer immunotherapies generate immune cells that are effective killers of blood cancers, but they have a hard time with solid tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 15, 2020 Category: Cancer & Oncology Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news

Designer probiotic treatment for cancer immunotherapy
(Columbia University School of Engineering and Applied Science) Columbia Engineers have engineered probiotics to safely deliver immunotherapies within tumors, including nanobodies against two proven therapeutic targets -- PD-L1 and CTLA-4. Continuously released by bacteria, the drugs continue to attack the tumor after just one dose, facilitating an immune response resulting in tumor regression. The versatile probiotic platform can also be used to deliver multiple immunotherapies simultaneously, enabling the release of effective therapeutic combinations within the tumor for more difficult-to-treat cancers like colorectal ca...
Source: EurekAlert! - Cancer - February 12, 2020 Category: Cancer & Oncology Source Type: news

Social control among immune cells improves defense against infections
(University of Freiburg) After infection, a simple mechanism ensures the balance between rapid expansion of immune cells and an excessive self-damaging reaction. This has now been deciphered by scientists at the University of Freiburg -- Medical Center (Germany) and international colleagues. The team has shown that activated T-cells are able to perceive each other and regulate their proliferation -- based on their density. The mechanism could help to improve cancer immunotherapies and was published in Immunity on Feb. 11. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 11, 2020 Category: Cancer & Oncology Source Type: news

Skysong Innovations Completes Licensing Agreement with ASU Spinout...
Immunotherapy company backed by $25 million in Series A financing is developing cancer treatments based on novel ASU technology(PRWeb February 10, 2020)Read the full story at https://www.prweb.com/releases/skysong_innovations_completes_licensing_agreement_with_asu_spinout_oncomyx_therapeutics/prweb16896350.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 10, 2020 Category: Pharmaceuticals Source Type: news

Mayo researchers discover way to prime cancer tumors for immunotherapy
(Mayo Clinic) A cancer tumor's ability to mutate allows it to escape from chemotherapy and other attempts to kill it. So, encouraging mutations would not be a logical path for cancer researchers. Yet a Mayo Clinic team and their collaborators took that counterintuitive approach and discovered that while it created resistance to chemotherapy, it also made tumors sensitive to immunotherapy. They also found that this approach worked successfully across tumor types and individual patient genomes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 7, 2020 Category: International Medicine & Public Health Source Type: news

New CAR-T target yields promising results for multiple myeloma
(Huntsman Cancer Institute) In research published today in the journal Nature Communications, Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy. Laboratory tests using mouse models and tumor cells from patients displayed promising results for this novel cellular immunotherapy for multiple myeloma and other types of blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2020 Category: Cancer & Oncology Source Type: news

Cancer vaccine could boost the effectiveness of immunotherapy
(Institute of Cancer Research) Supercharging the mutation rate in cancer cells can create a powerful vaccine that is able to boost the effectiveness of immunotherapy, a major new study reports. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2020 Category: Cancer & Oncology Source Type: news

Cold plasma patch could make immunotherapy more effective for treating melanoma, study finds
This study represents an important milestone for the field of plasma medicine,” said co-senior author Richard Wirz, professor of mechanical and aerospace engineering at UCLA Samueli. “It demonstrates that the microneedle patch can realize the plasma delivery while also working with the drug t o improve the effectiveness of cancer therapy.”“Plasma can generate reactive oxygen species and reactive nitrogen species, which are a group of chemical species that can destroy cancer cells,” said Guojun Chen, who is the co-first author of the study and a postdoctoral fellow in Gu’s laboratory.&ldq...
Source: UCLA Newsroom: Health Sciences - February 6, 2020 Category: Universities & Medical Training Source Type: news

New Immunotherapy Had Positive Results In Cancer Patients After Other Treatments Failed
A new type of cell-based immunotherapy has extended the lives of several people with blood cancer who had no treatment options left. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 6, 2020 Category: Pharmaceuticals Authors: Victoria Forster, Contributor Source Type: news

Dr. Chen Liu appointed the Brady Professor of Pathology
Liu is an expert in viral hepatitis, liver cancer immunotherapy, graft-versus-host disease, and cancer epigenetics. (Source: Yale Science and Health News)
Source: Yale Science and Health News - February 6, 2020 Category: Universities & Medical Training Source Type: news

Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
The report highlights recent advances in oncology medicine, including the emergence of novel systemic therapies, and progress in cancer prevention, molecular diagnostics, and cancer treatment —surgery, radiotherapy, combination therapy, immunotherapy, and other types of therapies (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 6, 2020 Category: Consumer Health News Source Type: news

Botanical drug is shown to help patients with head and neck cancers
In this study, UCLA researchers found that when APG-157 is taken through oral mucosal absorption, patients have high levels of curcumin circulating in their blood and absorbed by cancer tissues.METHODUCLA researchers conducted the study of APG-157 comparing 12 people who had oral and oropharyngeal cancer with a control group of 13 people who did not have cancer. The reason both the people with cancer and without cancer were part of the study was to show that the drug was not toxic to either people with cancer or those without cancer.The medication was given each hour for three hours and was delivered as a lozenge that slow...
Source: UCLA Newsroom: Health Sciences - February 6, 2020 Category: Universities & Medical Training Source Type: news

Butyrophilin 2A1 is essential for phosphoantigen reactivity by {gamma}{delta} T cells
Gamma delta () T cells are essential to protective immunity. In humans, most T cells express V9V2+ T cell receptors (TCRs) that respond to phosphoantigens (pAgs) produced by cellular pathogens and overexpressed by cancers. However, the molecular targets recognized by these TCRs are unknown. Here, we identify butyrophilin 2A1 (BTN2A1) as a key ligand that binds to the V9+ TCR chain. BTN2A1 associates with another butyrophilin, BTN3A1, and these act together to initiate responses to pAg. Furthermore, binding of a second ligand, possibly BTN3A1, to a separate TCR domain incorporating V2 is also required. This distinctive mode...
Source: ScienceNOW - February 6, 2020 Category: Science Authors: Rigau, M., Ostrouska, S., Fulford, T. S., Johnson, D. N., Woods, K., Ruan, Z., McWilliam, H. E. G., Hudson, C., Tutuka, C., Wheatley, A. K., Kent, S. J., Villadangos, J. A., Pal, B., Kurts, C., Simmonds, J., Pelzing, M., Nash, A. D., Hammet, A., Verhagen, Tags: Immunology, Online Only r-articles Source Type: news

Building a safer CAR-T therapy
(Ludwig Institute for Cancer Research) A Ludwig Cancer Research study has devised a new type of chimeric antigen-receptor (CAR) T cell -- a family of promising immunotherapies for cancer -- that can be switched on and off on demand. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 3, 2020 Category: International Medicine & Public Health Source Type: news

Cold plasma patch could make immunotherapy more effective for treating melanoma
(University of California - Los Angeles Health Sciences) An interdisciplinary team of researchers at the UCLA has developed a medicated patch that can deliver immune checkpoint inhibitors and cold plasma directly to tumors to help boost the immune response and kill cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 3, 2020 Category: Cancer & Oncology Source Type: news

Designing an emergency stop switch for immunotherapies
(Ecole Polytechnique F é d é rale de Lausanne) CAR T-cell therapy is a highly promising treatment strategy for tumors, but is associated with life-threatening side effects. Researchers at EPFL, UNIL and CHUV have developed a new way to " switch off " the therapy when a cancer patient's life is in danger, paving the way for safer immunotherapy approaches to target solid tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 3, 2020 Category: Cancer & Oncology Source Type: news

Math models add up to improved cancer immunotherapy
(Massachusetts General Hospital) A merger of math and medicine may help to improve the efficacy of immunotherapies, potentially life-saving treatments that enhance the ability of the patient's own immune system to attack cancerous tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 3, 2020 Category: Cancer & Oncology Source Type: news

Special Report: On the Receiving End of Immunotherapy Complications
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - February 1, 2020 Category: Emergency Medicine Tags: Special Report Source Type: news

Peanut allergy drug from Peninsula company approved by FDA
Aimmune Therapeutics Inc. ended a nearly nine-year quest Friday by winning Food and Drug Administration for a first-of-its-kind peanut allergy treatment that protects people from potentially lethal accidental exposures. The oral immunotherapy, a capsule of powderized peanut protein called Palforzia, is approved for kids ages 4-17 — a group whose parents kickstarted the Brisbane company's founding in 2011 after a venting meeting with clinicians, advocacy groups, regulators and drug developers. "They… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 1, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Treating Peanut Allergy: Insights From an Insider Treating Peanut Allergy: Insights From an Insider
Why all the hype about oral immunotherapy for peanut allergy? Dr Jonathan Spergel, an investigator in the clinical trials, shares his insights.CHOP Expert Commentary (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 1, 2020 Category: Allergy & Immunology Tags: Pediatrics Expert Interview Source Type: news

Peanut allergy drug from Peninsula company approved by FDA
Aimmune Therapeutics Inc. ended a nearly nine-year quest Friday by winning Food and Drug Administration for a first-of-its-kind peanut allergy treatment that protects people from potentially lethal accidental exposures. The oral immunotherapy, a capsule of powderized peanut protein called Palforzia, is approved for kids ages 4-17 — a group whose parents kickstarted the Brisbane company's founding in 2011 after a venting meeting with clinicians, advocacy groups, regulators and drug developers. "They… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 1, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Researchers identify possible new combination treatment for advanced melanoma
FINDINGSA study by researchers at the UCLA Jonsson Comprehensive Cancer Center suggests that using an immunotherapy drug called NKTR-214, also known as bempegaldesleukin, in combination with an infusion of anti-tumor immune cells, or T cells, may produce a stronger immune response that could help fight advanced melanoma.When tested in mice with melanoma tumors that were unlikely to stimulate an immune response, the approach increased the number of anti-tumor immune cells, and those immune cells lived longer and functioned better than the standard therapy, empowering the cells to destroy the tumor.BACKGROUNDAdoptive cell th...
Source: UCLA Newsroom: Health Sciences - January 31, 2020 Category: Universities & Medical Training Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product ...
Source: Roche Investor Update - January 31, 2020 Category: Pharmaceuticals Source Type: news

Researchers identify possible new combination treatment for advanced melanoma
(University of California - Los Angeles Health Sciences) Immunotherapy drug in combination with an infusion of anti-tumor immune cells may produce a stronger immune response that could help fight advanced melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 31, 2020 Category: Cancer & Oncology Source Type: news

Immunitor unveils breakthrough immunotherapy to treat tuberculosis in...
Immunitor Inc., commercial-stage biotech company, is pleased to announce the publication of positive results from the randomized, placebo-controlled Phase III clinical trial for Tubivac (V7), the...(PRWeb January 31, 2020)Read the full story at https://www.prweb.com/releases/immunitor_unveils_breakthrough_immunotherapy_to_treat_tuberculosis_in_as_short_as_one_month/prweb16874150.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 31, 2020 Category: Pharmaceuticals Source Type: news

Penn researchers identify cancer cell defect driving resistance to CAR T cell therapy
(University of Pennsylvania School of Medicine) Some cancer cells refuse to die, even in the face of powerful cellular immunotherapies like CAR T cell therapy, and new research is shedding light on why. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 30, 2020 Category: International Medicine & Public Health Source Type: news

Neoadjuvant checkpoint blockade for cancer immunotherapy
Cancer immunotherapies that target the programmed cell death 1 (PD-1):programmed death-ligand 1 (PD-L1) immune checkpoint pathway have ushered in the modern oncology era. Drugs that block PD-1 or PD-L1 facilitate endogenous antitumor immunity and, because of their broad activity spectrum, have been regarded as a common denominator for cancer therapy. Nevertheless, many advanced tumors demonstrate de novo or acquired treatment resistance, and ongoing research efforts are focused on improving patient outcomes. Using anti–PD-1 or anti–PD-L1 treatment against earlier stages of cancer is hypothesized to be one such ...
Source: ScienceNOW - January 30, 2020 Category: Science Authors: Topalian, S. L., Taube, J. M., Pardoll, D. M. Tags: Immunology, Medicine, Diseases, Online Only review Source Type: news

Roche's Tecentriq Fails Trial in Form of Urothelial Cancer Roche's Tecentriq Fails Trial in Form of Urothelial Cancer
Roche's immunotherapy Tecentriq failed a late-stage clinical trial in a form of urothelial cancer, the Swiss drugmaker said on Friday.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 28, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

ONCOS-102 Shows Promise in Combination Mesothelioma Treatment
ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going ...
Source: Asbestos and Mesothelioma News - January 27, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - January 27, 2020 Category: Pharmaceuticals Source Type: news

New cancer center established at Johns Hopkins University
(The Mark Foundation for Cancer Research) Bringing together the tools of astronomy image analysis, pathology, computer science, cancer genomics, and immunogenomics to solve problems in oncology, the new center will find innovative solutions that can expand the number of cancer patients who benefit from immunotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 27, 2020 Category: International Medicine & Public Health Source Type: news

Medical News Today: Cancer: Using copper to boost immunotherapy
Scientists have successfully destroyed cancer cells in mice by using copper-based nanoparticles and immunotherapy.   Importantly, the cancer did not return. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 25, 2020 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

HPV-Cancer Targeting Immunotherapy Enters Phase 1 Clinical Trial After Showing Success In Animals
The paper highlights the candidate ’s ability to target and shrink HPV motivated tumors in both animal studies and human blood samples. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 24, 2020 Category: Pharmaceuticals Authors: Dana Dovey, Contributor Source Type: news

Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer
Basel, 24 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasiv e urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we w...
Source: Roche Media News - January 24, 2020 Category: Pharmaceuticals Source Type: news

Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer
            Basel, 24 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasiv e urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is ve...
Source: Roche Investor Update - January 24, 2020 Category: Pharmaceuticals Source Type: news

Top 5 Advances in Lung Cancer Immunotherapy Over the Past Decade Top 5 Advances in Lung Cancer Immunotherapy Over the Past Decade
Lung cancer experts Jack West and Charu Aggarwal highlight the biggest immunotherapy trials in thoracic oncology from 2010 to 2019.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

B Cells, Tertiary Lymphoid Structures Promote Cancer Immunotherapy Responses B Cells, Tertiary Lymphoid Structures Promote Cancer Immunotherapy Responses
B cells and tertiary lymphoid structures (TLS) play key roles in promoting cancer immunotherapy responses, according to results from three studies published in Nature.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 22, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news